SCHEMBL3107325

SCHEMBL3107325

Cc1nc(CNC[C@@H]2CCCN2C)n(-c2ccc(S(N)(=O)=O)cc2)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 4/20 0.38
EPHX2 P34913 5/20 0.38
MALT1 Q9UDY8 1/20 0.38
CA2 P00918 7/20 0.38
CA1 P00915 6/20 0.38
CA9 Q16790 6/20 0.38
CA12 O43570 5/20 0.38
DRD2 P14416 2/20 0.36
DRD1 P21728 2/20 0.36
DRD4 P21917 2/20 0.36
DRD3 P35462 2/20 0.36
CYP1A2 P05177 2/20 0.36
CYP2D6 P10635 2/20 0.36
CA3 P07451 1/20 0.36
ADRA2A P08913 1/20 0.36
MAPT P10636 1/20 0.36
PTGS1 P23219 1/20 0.36
CA6 P23280 1/20 0.36
CA5A P35218 1/20 0.36
CA7 P43166 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3118228 0.79 CA1 (0.46) PTGS2CA2CA1CA9CA12
SCHEMBL3111533 0.73 CA1 (0.42) PTGS2CA2CA1CA9CA12
SCHEMBL3109487 0.73 CA1 (0.51) PTGS2CA2CA1CA9CA12
SCHEMBL3113178 0.71 CA1 (0.55) PTGS2CA2CA1CA9CA12
SCHEMBL3114269 0.71 CA2 (0.43) PTGS2CA2CA1CA9CA12
SCHEMBL13099818 0.71 PTGS2 (0.52) PTGS2CA2CA1CA9CA12
SCHEMBL3112101 0.68 CA1 (0.46) PTGS2CA2CA1CA9CA12
SCHEMBL3105858 0.67 CA1 (0.53) PTGS2CA2CA1CA9CA12
SCHEMBL3114428 0.66 CA1 (0.57) PTGS2CA2CA1CA9CA12
SCHEMBL3108487 0.65 CHRNA7 (0.43) PTGS2CA2CA1CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100256357-A1 HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE AGOURON PHARMACEUTICALS, INC. 2010-10-07 US disclosed
US-20100256357-A1 HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE AGOURON PHARMACEUTICALS, INC. 2010-10-07 US disclosed
US-20100256357-A1 HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE AGOURON PHARMACEUTICALS, INC. 2010-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256357-A1 HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE CA2, CA7, CA9 PTGS2 47/4885EPHX2 951/4885MALT1 2844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.